相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Deciphering the immunopeptidome in vivo reveals new tumour antigens
Alex M. Jaeger et al.
NATURE (2022)
Engineering soluble T-cell receptors for therapy
Ross A. Robinson et al.
FEBS JOURNAL (2021)
Evolution of CD8+ T Cell Receptor (TCR) Engineered Therapies for the Treatment of Cancer
Yimo Sun et al.
CELLS (2021)
The landscape of bispecific T cell engager in cancer treatment
Shujie Zhou et al.
BIOMARKER RESEARCH (2021)
Perspective: Designing T-Cell Engagers With Better Therapeutic Windows
Omid Vafa et al.
FRONTIERS IN ONCOLOGY (2020)
Format and geometries matter: Structure-based design defines the functionality of bispecific antibodies
Steffen Dickopf et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2020)
Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma
Mark R. Middleton et al.
CLINICAL CANCER RESEARCH (2020)
A review of bispecific antibodies and antibody constructs in oncology and clinical challenges
Frans V. Suurs et al.
PHARMACOLOGY & THERAPEUTICS (2019)
Novel TCR-based biologics: mobilising T cells to warm 'cold' tumours
Kate L. Lowe et al.
CANCER TREATMENT REVIEWS (2019)
Direct Detection and Quantification of Neoantigens
Qing Wang et al.
CANCER IMMUNOLOGY RESEARCH (2019)
TCR Fingerprinting and Off-Target Peptide Identification
Armen R. Karapetyan et al.
FRONTIERS IN IMMUNOLOGY (2019)
Bispecific T-cell engagers: Towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety
Diego Ellerman
METHODS (2019)
Targeting cancers through TCR-peptide/MHC interactions
Qinghua He et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Targeting transcription factors in cancer - from undruggable to reality
John H. Bushweller
NATURE REVIEWS CANCER (2019)
Survivin expression as an independent predictor of overall survival in pancreatic adenocarcinoma
John Contis et al.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS (2018)
Prognostic role of survivin in patients with glioma
Sunfu Zhang et al.
MEDICINE (2018)
High nuclear Survivin expression as a poor prognostic marker in pancreatic ductal adenocarcinoma
Li Zhou et al.
JOURNAL OF SURGICAL ONCOLOGY (2018)
Survivin: a unique target for tumor therapy
Himani Garg et al.
CANCER CELL INTERNATIONAL (2016)
Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma
Robert A. Fenstermaker et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Blinatumomab, a Bispecific T-cell Engager (BiTE®) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications
Min Zhu et al.
CLINICAL PHARMACOKINETICS (2016)
Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside
Chantal Kuhn et al.
IMMUNOTHERAPY (2016)
Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors
Daniel T. Harris et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2016)
Blinatumomab: A First-in-Class Bispecific T-Cell Engager for Precursor B-Cell Acute Lymphoblastic Leukemia
Larry W. Buie et al.
ANNALS OF PHARMACOTHERAPY (2015)
Tissue-based map of the human proteome
Mathias Uhlen et al.
SCIENCE (2015)
Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients
Neil L. Berinstein et al.
ONCOIMMUNOLOGY (2015)
Survivin-specific T cell receptor targets tumor but not T cells
Caroline Arber et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors
Volker Lennerz et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Targeting Tumor Suppressor Networks for Cancer Therapeutics
Xuning Emily Guo et al.
CURRENT DRUG TARGETS (2014)
Six-locus high resolution HLA haplotype frequencies derived from mixed-resolution DNA typing for the entire US donor registry
Loren Gragert et al.
HUMAN IMMUNOLOGY (2013)
Examining the presentation of tumor-associated antigens on peptide-pulsed T2 cells
Giovanna Bossi et al.
ONCOIMMUNOLOGY (2013)
Survivin is highly expressed in CD34+38- leukemic stem/progenitor cells and predicts poor clinical outcomes in AML
Bing Z. Carter et al.
BLOOD (2012)
Identification and engineering of human variable regions that allow expression of stable single-chain T cell receptors
David H. Aggen et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2011)
MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors
Matthias Leisegang et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Oncogenic mutations as predictive factors in colorectal cancer
A. Lievre et al.
ONCOGENE (2010)
The molecular basis of TCR germline bias for MHC is surprisingly simple
K. Christopher Garcia et al.
NATURE IMMUNOLOGY (2009)
Quantifying and imaging NY-ESO-1/LAGE-1-derived epitopes on tumor cells using high affinity T cell receptors
Marco A. Purbhoo et al.
JOURNAL OF IMMUNOLOGY (2006)
Antigen degradation or presentation by MHC class I molecules via classical and non-classical pathways
M Grommé et al.
MOLECULAR IMMUNOLOGY (2002)
Gene-expression profiles predict survival of patients with lung adenocarcinoma
DG Beer et al.
NATURE MEDICINE (2002)
分享论文
